- Home
- SEED vs JAGX Comparison
SEED vs JAGX Comparison
Compare SEED & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- JAGX
- Stock Information
- Founded
- SEED 1997
- JAGX 2013
- Country
- SEED China
- JAGX United States
- Employees
- SEED N/A
- JAGX N/A
- Industry
- SEED Farming/Seeds/Milling
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- SEED Consumer Staples
- JAGX Health Care
- Exchange
- SEED Nasdaq
- JAGX Nasdaq
- Market Cap
- SEED 12.1M
- JAGX 12.9M
- IPO Year
- SEED N/A
- JAGX N/A
- Fundamental
- Price
- SEED $1.83
- JAGX $0.85
- Analyst Decision
- SEED
- JAGX
- Analyst Count
- SEED 0
- JAGX 0
- Target Price
- SEED N/A
- JAGX N/A
- AVG Volume (30 Days)
- SEED 38.9K
- JAGX 542.5K
- Earning Date
- SEED 02-19-2025
- JAGX 11-13-2024
- Dividend Yield
- SEED N/A
- JAGX N/A
- EPS Growth
- SEED N/A
- JAGX N/A
- EPS
- SEED 1.21
- JAGX N/A
- Revenue
- SEED $16,516,031.00
- JAGX $10,480,000.00
- Revenue This Year
- SEED N/A
- JAGX $18.18
- Revenue Next Year
- SEED N/A
- JAGX $40.06
- P/E Ratio
- SEED $1.51
- JAGX N/A
- Revenue Growth
- SEED 64.93
- JAGX N/A
- 52 Week Low
- SEED $1.37
- JAGX $0.84
- 52 Week High
- SEED $6.38
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- SEED 29.66
- JAGX 39.11
- Support Level
- SEED $1.64
- JAGX $0.84
- Resistance Level
- SEED $2.00
- JAGX $1.33
- Average True Range (ATR)
- SEED 0.16
- JAGX 0.10
- MACD
- SEED -0.01
- JAGX -0.03
- Stochastic Oscillator
- SEED 29.23
- JAGX 1.04
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.